<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138722">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01295112</url>
  </required_header>
  <id_info>
    <org_study_id>TRA-OZAB-11-001</org_study_id>
    <nct_id>NCT01295112</nct_id>
  </id_info>
  <brief_title>Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion</brief_title>
  <official_title>Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Retina Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®)
      eye injections reduces the need for repeat bevacizumab eye injections in patients with
      nonischemic central retina vein occlusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter clinical study designed to determine if the addition of Ozurdex®
      injection to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab
      eye injections in patients with nonischemic central retina vein occlusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the total number of PRN bevacizumab intravitreal injections through 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary efficacy endpoint is the visual acuity score based on best corrected visual acuity (BCVA) at Week 24</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Non-Ischemic Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Active bevacizumab (Avastin®) and Sham Ozurdex®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active bevacizumab (Avastin®) and Active Ozurdex®</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active bevacizumab and Sham dexamethasone</intervention_name>
    <description>Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Avastin® (bevacizumab)</other_name>
    <other_name>Ozurdex® (dexamethasone intravitreal implant)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active bevacizumab and Active dexamethasone</intervention_name>
    <description>Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Avastin® (bevacizumab)</other_name>
    <other_name>Ozurdex® (dexamethasone intravitreal implant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male or female subjects (aged 18 or older);

          2. provide written informed consent and sign/date a health information release;

          3. women of childbearing potential must be willing to practice effective contraception
             for the duration of the study.

        Exclusion Criteria:

          1. any systemic disease or clinical evidence of any condition which would make the
             subject, in the opinion of the investigator, unsuitable for the study or could
             potentially confound the study results;

          2. use of systemic steroids within 1 month prior to Baseline Visit (Visit 1) or
             anticipated use at any time during the study (inhaled and intranasal steroids are
             allowed);

          3. sitting systolic blood pressure equal to or greater than 160 mmHg or diastolic blood
             pressure equal to or greater than 100 mmHg at the Baseline Visit (Visit 1);

          4. use of warfarin, heparin, enoxaparin or similar anticoagulants within 2 weeks prior
             to Baseline Visit (Visit 1) or anticipated use at any time during the study;

          5. known allergy or hypersensitivity to the study medications or their components;

          6. previous enrollment in an Ozurdex® clinical trial or previous use of an Ozurdex®
             implant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Csaky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Retina Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 20, 2016</lastchanged_date>
  <firstreceived_date>February 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Retina Associates</investigator_affiliation>
    <investigator_full_name>Karl Csaky</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
